Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma
International Journal of Urology · 2025
DOI: 10.1111/iju.70162 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von Satoshi Inoue und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Maintenance Chemotherapy, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
The association between the response to first‐line chemotherapy and maintenance of avelumab remains unclear. We identified factors associated with the response to avelumab in patients with advanced urothelial carcinoma using real‐world data.
Methods
We retrospectively enrolled 100 patients with advanced urothelial carcinoma treated with maintenance avelumab therapy between March 2021 and April 2024 at Nagoya University and nine affiliated hospitals. The complete/partial‐response group was defined as patients with complete response or partial response as the best response to first‐line chemotherapy. The stable disease group was defined as patients with stable disease as the best response to first‐line chemotherapy.
Results
Seven patients (7.0%) achieved complete response, 65 (65.0%) achieved partial response, and 28 (28.0%) achieved stable disease as the best response to first‐line chemotherapy. Regarding avelumab therapy, the complete/partial‐response group had significantly better progression‐free survival than the stable disease group (median: 11.1 vs. 3.2 months, p < 0.001). In multivariate analyses, the best response to first‐line chemotherapy was the only independent risk factor for progression‐free survival (hazard ratio = 1.844, 95% confidence interval = 1.002–3.394; p = 0.049). Overall survival was significantly shorter in the stable disease group than in the complete/partial‐response group (median: 14.1 months vs. not reached, p < 0.001). Multivariate analyses revealed significant associations between poor overall survival and performance status (hazard ratio = 2.175, 95% confidence interval = 1.030–4.592; p = 0.042) and the best response to first‐line chemotherapy (hazard ratio = 4.174, 95% confidence interval = 1.975–8.824; p < 0.001).
Conclusions
The best response to first‐line chemotherapy may predict the clinical outcome of patients with advanced urothelial carcinoma treated with avelumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Urology, Yokkaichi Municipal Hospital, Yokkaichi, Japan.
- Department of Urology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
- Department of Urology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
- Department of Urology, Toyohashi Municipal Hospital, Toyohashi, Japan.
- Department of Urology, Chukyo Hospital, Nagoya, Japan.
ORCID-Profile: Satoshi Inoue
Zitieren
APA
Inoue, S., Hayakawa, A., Kobayashi, M., Nagasaka, Y., Omi, T., Shamoto, N., Ito, F., Yuba, T., Yuguchi, Y., Kawanishi, H., Tochigi, K., & Akamatsu, S. (2025). Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma. International Journal of Urology. https://doi.org/10.1111/iju.70162
Vancouver
Inoue S, Hayakawa A, Kobayashi M, Nagasaka Y, Omi T, Shamoto N, et al. Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma. International Journal of Urology. 2025. doi:10.1111/iju.70162
BibTeX
@article{Inoue2025,
author = {Inoue, Satoshi and Hayakawa, Akira and Kobayashi, Mikinori and Nagasaka, Yuriko and Omi, Takanao and Shamoto, Noritoshi and Ito, Fumihiro and Yuba, Takuma and Yuguchi, Yuri and Kawanishi, Hideji and Tochigi, Kosuke and Akamatsu, Shusuke},
title = {Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70162}
}
EUVIMED